Objective: To summarize published data on pharmacologic treatments for alcohol dependence alone and in combination with brief psychosocial therapies that may be feasible for primary care and specialty medical settings. Methods: We conducted electronic searches of published original research articles and reviews in MEDLINE, SCOPUS, CINAHL, Embase, and PsychINFO. In addition, hand searches of reference lists of review articles, supplemental searches of internet references and contacts with experts in the field were conducted. Randomized controlled studies published between January 1960 and August 2010 that met our inclusion/exclusion criteria were included. Results: A total of 85 studies, representing 18,937 subjects, met our criteria for inclusion. The evidence base for oral naltrexone (6% more days abstinent than placebo in the largest study) and topiramate (prescribed off-label) (e.g., 26.2% more days abstinent than placebo in a recent study) is positive but modest. Acamprosate shows modest efficacy with recently abstinent patients, with European studies showing better results than U.S. ones. The evidencebase for disulfiram is equivocal. Depot naltrexone shows efficacy (25% greater reduction in rate of heavy drinking vs. placebo, in one of the largest studies) in a limited number of studies. Some studies suggest that patients do better with extensive psychosocial treatments added to medications while others show that brief support can be equally effective. Conclusions: Although treatment effects are modest, medications for alcohol dependence, in conjunction with either brief support or more extensive psychosocial therapy, can be effective in primary and specialty care medical settings.
1. summarizes data on multiple drug therapies rather than focusing on only one medication; 2. is a formal systematic review in its approach; and 3. interprets evidence-based findings primarily for practicing clinicians.
METHODS

Literature Search and Study Selection
In August 2010, we conducted:
1. electronic searches of published and "in press" original research articles and reviews in MEDLINE, Embase, SCOPUS, CINAHL, and PsycINFO; 2. hand searches of reference lists of review articles; 3. supplemental searches of internet references; and 4. searches by contacting experts in the field. Time periods of searches included 1960 to August, 2010. Search terms included alcohol abuse, alcohol dependence, alcohol use disorder, alcoholics, alcoholism, alcohol pharmacotherapy, naltrexone, acamprosate, topiramate, disulfiram, antidepressants, ondansetron, nalmefene, serotonergic agents, brief intervention, and physician intervention. Specific inclusion and exclusion criteria are included in Table 1 .
Study Selection
Two authors independently reviewed all titles and abstracts to identify relevant articles. Articles that met inclusion/exclusion criteria were independently abstracted by the two authors. Discrepancies were resolved by repeated review and discussion, with the principal author serving as the final arbiter to resolve conflict. The flow diagram in Figure 1 shows an overview of the study selection process.
Assessment for Potential Bias
Two authors independently rated each study using the Jadad scale, which focuses on the authors' description of randomization, blinding, and study withdrawals [11] . Studies rated 4 or 5 by both independent raters were categorized as "Less Potential for Bias," while those receiving a 1, 2, or 3 were labeled "Higher Potential for Bias." It is important to note that the Jadad assessment does not evaluate all sources of bias (e.g., as may arise in data analysis or reporting of the study results). Discrepancies were resolved by repeated review and discussion, with the principal author serving as the final arbiter to resolve conflict.
RESULTS
Our searches identified 85 randomized controlled trials (RCTs), representing 18,937 subjects, that met all inclusion/exclusion criteria and underwent full text review. Results are presented separately for each medication and also those including medication/psychosocial interactions. Some studies evaluated the efficacy of more than one active medication and are included in more than one section. Tables 2 through 7 list studies for each medication, providing first author, year of publication, Jadad score, number of subjects, length of follow-up, and results. Sample size inadequate to detect at least a moderate treatment effect on the primary alcohol consumption outcome (e.g., studies using a subject sample of less than 30 per group for a continuous outcome were excluded) Figure 1 . Article selection. Total abstinence greater and time to relapse longer for naltrexone and sertraline group than for other three groups None reported 
Disulfiram
Disulfiram (Antabuse ® ), FDA-approved to treat alcohol dependence in 1951, interferes with the metabolism of alcohol, by inhibiting aldehyde dehydrogenase, and produces flushing, nausea, palpitations, and other severe reactions if drinking occurs. A total of 11 RCTs that evaluated the efficacy of disulfiram met our criteria for inclusion. Of these, two studies, although methodologically sound, investigated disulfiram tablets implanted in the abdomen [12, 13] . Since evidence is lacking for the bioavailability of implanted disulfiram tablets [14] , results of these studies were not included in our conclusions. Of the remaining nine RCTs, only one study was rated in the "Less Potential for Bias" category. This study compared a placebo with two doses of disulfiram, one "active" 250 mg dose and one "inactive" 1 mg dose [15] . No significant differences were found between disulfiram and placebo on any alcohol consumption measure. It might be noted that drug ingestion was unsupervised and the authors found a significant relationship between compliance and abstinence.
Eight other studies were judged to be in the "Higher Potential for Bias" category. These studies compared disulfiram either with placebo or with acamprosate, naltrexone, or topiramate. The two studies comparing disulfiram with placebo found significant reductions in alcohol consumption. Fuller et al. [16] , in a Veterans Administration Cooperative Study, reported significantly fewer drinking days over a 1-year time period but no differences in total abstinence or time to first drink. Chick et al. [17] found significant increases in number of abstinent days (100 for disulfiram vs. 69 for placebo over 6 months) and change in 6-month alcohol consumption. In both of these studies, close relatives were actively involved in the patient's treatment, with disulfiram ingestion being supervised daily in the Chick study.
Three studies compared supervised disulfiram to oral naltrexone, with results favoring disulfiram in two studies [18, 19] . The third study, with blinded naltrexone and blinded placebo but open-label disulfiram, found that all active medications had better alcohol outcomes than placebo, with no advantage to combined medications [20] .
Two studies included an acamprosate comparison group, with one comparing supervised disulfiram with acamprosate and another comparing disulfiram with acamprosate alone and naltrexone alone. Both of these studies favored disulfiram [19, 21] . The one study that compared supervised disulfiram with topiramate found disulfiram to be significantly more effective than topiramate in delaying the onset of relapse (133 days vs. 79 days) [22] . After 9 months of treatment, 90% of disulfiram patients were abstinent, compared to 56% for topiramate.
Topiramate
The anti-epileptic topiramate (Topamax ® ), although not FDA-approved for alcohol dependence, targets both the GABA and glutamate brain pathways and reduces alcohol craving. Four topiramate studies met our criteria for inclusion. Of these, three were categorized as having "Less Potential for Bias" [23] [24] [25] . All three studies found topiramate to be superior to placebo on all drinking measures. In the largest of these studies, Johnson et al. [25] found that topiramate, compared to placebo, decreased percentage of heavy drinking days (mean difference of 16.19%; CI, 10.79%-21.60%) and all other drinking outcome measures. One of these three studies also included a naltrexone comparison group [23] . In that study, topiramate was superior to placebo but not to naltrexone. Naltrexone did not differ statistically from placebo. A fourth study, rated as "Higher Potential for Bias," compared topiramate with naltrexone and found no difference by treatment [26] . Abstinence did not differ by treatment at 3 or 6 months. No placebo group was included.
Antidepressants
Seven RCTs focusing on selective serotonin reuptake inhibitors (SSRIs) met our criteria and all were rated as having "Less Potential for Bias." Four compared sertraline to placebo (one with alcohol dependent subjects with comorbid PTSD, two included subjects with comorbid major depression, and one included alcoholic subjects with lifetime depression) [27] [28] [29] [30] . Three of these studies failed to show significant differences in any of several drinking outcomes by treatment group. One (which included adjunctive cognitive behavior therapy) found sertraline to result in fewer drinks per drinking day but no differences in time to first drink, time to first heavy drinking day, or in abstinence rates [27] . Kranzler et al. compared fluoxetine versus placebo and found no significant medication effects on drinking measures [31] .
Two recent studies investigated sertraline in combination with naltrexone. Farren, et al. [32] found that, although there were trends toward favoring a sertraline/naltrexone combination compared to a placebo/naltrexone combination, no statistically significant differences were evident. Conversely, with alcohol dependent patients with comorbid depression, Pettinati et al. [33] found greater total abstinence (54%) when naltrexone and sertraline were used in combination. The combined abstinence rate for sertraline alone, naltrexone alone, and placebo was only 24%.The combination of naltrexone and sertraline also led to significantly better outcomes on percent of subjects not drinking heavily, time to relapse, and time to any drinking.
One study investigated the tricyclic antidepressant, desipramine, versus placebo, stratified on depression [34] . During the 6-month study there was a decreased relapse for desipramine relative to placebo. The interaction between depression and medication was not significant.
Two studies found that quetiapine, an antipsychotic mood stabilizer, as an adjunct to lithium or divalproex with alcohol dependent patients with biopolar I disorder, did not result in reduction in drinking outcome measures.
Acamprosate
Acamprosate (Campral ® ) was FDA-approved for the treatment of alcohol dependence in 2004. While its mechanism is not entirely understood, evidence suggests that it interacts with the glutamate neurotransmitter system, reducing protracted (post-acute) withdrawal symptoms including insomnia, restlessness, and anxiety. A total of 24 RCTs evaluating acamprosate met our inclusion/exclusion criteria. Of these, 15 were rated as having "Less Potential for Bias" [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] . Eleven compared acamprosate to placebo, three included naltrexone as a comparison group in addition to placebo, and one had a disulfiram comparison group.
Results of the 11 placebo comparison studies were mixed. Six studies showed changes in drinking outcomes favoring acamprosate [47] [48] [49] [50] [51] . For example, Pelc et al. [47] compared 1332 mg/day and 1998 mg/day of acamprosate with placebo in a 90-day trial. Both levels of acamprosate led to better cumulative abstinence duration (51.9 days, 56.6 days vs. 34.3 days), time to first relapse (55.5 days, 56.3 days vs. 15 days), and total abstinence (41%, 41% vs. 15%) than placebo. Poldrugo [48] found that the percentage of patients with continuous abstinence after 6 months of treatment was almost double for the acamprosate group (40.7%) compared to the placebo group (20.8%).
Five other studies either had mixed results or showed no significant differences between acamprosate and placebo. Using 2 g and 3 g of acamprosate versus placebo, Mason found no significant differences in percent alcohol free days or quantity/frequency of drinking. Post-hoc analyses, however, revealed a significantly higher percentage of abstinent days for acamprosate over placebo in subjects who were abstinent at baseline. At the end of a 6-month study, Gual [11] found significantly higher cumulative days abstinent and days from last relapse in the acamprosate group, but abstinence throughout the trial was not statistically significant. Three other studies found no significant differences between acamprosate and placebo on any drinking outcome measure [17, 40, 46] .
Of three studies comparing acamprosate to both placebo and naltrexone, Kiefer, et al. [42] found, in a 12-week trial, that acamprosate was superior to placebo on abstinence (~28% vs.~8%) and on no relapse to heavy drinking days (~40% vs.~28%). Both acamprosate and naltrexone were equally effective and their combination was superior to acamprosate alone but not naltrexone alone. However, in two large multi-center RCTs, Anton et al. [7] in the Combine Study in the United States and Morley et al. in Australia [45] , found no effect for acamprosate over placebo. In addition, the Combine study showed no advantage of the combination of acamprosate and naltrexone. Morley's Australian study found neither acamprosate nor naltrexone were superior to placebo except in the case of subjects with low baseline dependence and depression, for which the efficacy of naltrexone was supported for relapse prevention.
Of the 8 studies rated as "Higher Potential for Bias," results were similarly mixed. In four of these studies comparing acamprosate to placebo, acamprosate was superior to placebo [52] [53] [54] [55] [56] . In three studies comparing acamprosate to other medications, two found disulfiram to be superior to acamprosate and one found naltrexone to be superior to acamprosate.
Finally, one study that is particularly relevant to the focus of this review compared open label acamprosate to standard care alone in primary care settings [57] . Cumulative abstinence over 1 year was higher in the acamprosate group than the standard care group, but, the absence of a placebo control group limits the implications of this naturalistic study.
It might be noted that there is a trend for European studies to show positive results, while U.S. studies are more mixed or negative. Mason has observed that these trials differed on several variables (e.g., a significantly larger number of U.S. subjects, compared to European subjects, had not discontinued drinking prior to randomization), all of which are considered predictors of poor treatment outcomes in clinical trials [58] .
Naltrexone
Oral naltrexone (ReVia ® ; Depade ® ), FDA-approved for alcohol dependence in 1994, and extended-release injectable naltrexone (Vivitrol ® ), approved in 2006, block opioid receptors, inhibiting rewarding effects of alcohol and reducing craving. By far, naltrexone is the most researched medical treatment for alcohol dependence. A total of 33 naltrexone RCTs met our criteria for inclusion in this review [7, 18-20, 23, 26, 32, 33, 39, 42, 45, 59-80] . Of these, the majority investigated oral naltrexone, with two focusing on depot naltrexone.
Of the 31 studies of oral naltrexone, 17 received a "Less Potential for Bias" rating. Fifteen of these compared naltrexone with a placebo. Of these, the majority, 12 studies, found naltrexone to be significantly superior to placebo on drinking outcomes. Three others found naltrexone to be no better than placebo [23, 68, 73] . One of these negative studies was the multicenter Veterans Affairs Naltrexone Cooperative Study which included patients with chronic, severe alcohol dependence, the majority of whom had family histories of alcoholism [68] . Another negative study targeted women with eating disorders [73] .
Two other studies evaluated the combined effects of oral naltrexone and sertraline, an SSRI antidepressant. In non-depressed alcohol dependent subjects, Farren et al. [32] did not find evidence for the superiority of the combination over naltrexone alone. Pettinati et al. [33] , however, found that, with depressed alcohol dependent subjects, the naltrexone/sertraline combination resulted in a higher abstinence rate (53.7%) than either naltrexone alone (21.3%), sertraline alone (27.5%), or placebo (23.1%).
Two studies evaluated depot naltrexone, a more recent form of naltrexone that is administered in monthly injections. Kranzler et al. [67] evaluated monthly depot injections for 3 months versus placebo injections. Time to first drinking day and number of abstinent days (52.8 vs. 45.6) favored naltrexone. In a larger and longer (6 months) multisite study, Garbutt et al. [61] found a 25% and 17% (based on doses of 380 mg vs. 190 mg) decrease in number of heavy drinking days for the naltrexone group compared to the placebo group.
Fifteen remaining studies were rated "Higher Potential for Bias" [18-20, 26, 62, 64-66, 72, 74-76, 78, 79, 81-83] . The majority of these investigations supported the efficacy of naltrexone over placebo. Two produced mixed results [72, 82] . One, without a placebo control group, found that disulfiram was superior to naltrexone and another found naltrexone and acamprosate to be comparable (again, no placebo control) [18, 19] .
Less Studied Medications
Seven RCTS examined the efficacy of a number of less studied drugs. All of these received a "Less Potential for Bias" rating. Two investigations evaluated baclofen, a GABA B receptor agonist that may reduce withdrawal symptoms and inhibit cravings, versus placebo with one (using patients with liver cirrhosis) finding an advantage to baclofen and another (using outpatient volunteers) finding no difference compared to placebo [84, 85] . Three other projects studied nalmefene, an opioid receptor agonist that can lessen cravings and reduce the reinforcing properties of alcohol, with two finding reduction in heavy drinking days compared to placebo and one finding no difference with a placebo [86] [87] [88] . Many of the subjects in one of these positive studies were primary care patients treated with the medication plus simple medical management [87] . Two studies found ondansetron, a 5-HT 3 receptor antagonist that can block the rewarding effects of alcohol, effective compared to placebo [89, 90] . Other less studied medications, with only one otherwise eligible RCT identified, were not included in this review (refer to Exclusion Criteria in Table 1 ).
Medication/Psychosocial Intervention Interaction
The question of whether brief psychosocial or supportive interventions add to the efficacy of alcohol dependence medications has received some research attention, although it is limited. In the vast majority of studies described above, all subjects, both active medication and placebo, received some type of adjuvant psychological intervention. Eleven studies have examined this issue separately in medication trials, with seven being judged as having "Less Potential for Bias." Results of four of these seven studies conclude that either cognitive behavior therapy (CBT), coping skills training, communication skills training, or broad spectrum treatment (a combination of CBT, Motivational Enhancement Therapy (MET), community reinforcement approaches, and 12-step methods), in combination with naltrexone, significantly improved drinking outcomes compared to either naltrexone alone or naltrexone with brief motivational support or standard medical care [60, 74, 91, 92] . The remaining three of the seven, including the large multicenter COMBINE study, showed that minimal support in the presence of naltrexone was as effective as medication with more intensive psychosocial intervention [7, 93, 94] . All three studies are relevant to alcoholism treatment in primary care since, in addition to medication, one used medical management (MM) (a supportive, compliance-focused intervention potentially adaptable to primary care settings), another treated a cohort of primary care patients with low intensity support, and another included infrequent consultation with a physician. Of the four studies rated "Higher Potential for Bias," one showed naltrexone plus coping skills training superior to naltrexone plus supportive therapy and three showed no significant advantage to adding extensive psychosocial treatments to naltrexone or acamprosate over brief support [64, 72, 95, 96] . In fact, O'Malley et al. [72] found that primary care management (PCM) plus naltrexone produced comparable results to cognitive behavior therapy (CBT) plus naltrexone in the short term (10 weeks) and produced better results in terms of maintenance of improvement over time.
DISCUSSION
Research findings on the efficacy of medical treatments for alcohol dependence are generally mixed. While overall treatment effects for these medications have been quite modest, it is clear that some alcohol dependent patients will benefit from pharmacotherapy. Unfortunately for clinical practice, objective clinical predictors of individual treatment response to specific medications are currently unavailable.
Nevertheless, our review found several evidence-based results that support a role for alcohol dependence treatment in medical settings. First, the one study with the highest Jadad score showed no advantage for disulfiram over placebo using an unsupervised disulfiram protocol. However, the majority of studies found that supervised disulfiram is more effective than placebo, with some evidence that it may be more efficacious than naltrexone, acamprosate, and topiramate. Compliance is a major problem with disulfiram and daily supervision of ingestion appears to be an essential key to clinical success. Second, evidence suggests that topiramate is an efficacious treatment for alcohol dependence, although the number of studies is small. Third, there is little evidence to support the use of antidepressants (either SSRIs or tricyclics) for alcohol dependence although one recent RCT found the combination of sertraline and naltrexone more effective with depressed alcoholics than naltrexone alone. Fourth, acamprosate may increase abstinence, although studies show mixed results, with some larger multisite studies in the United States (e.g., the Combine Study) showing no advantage over placebo and European studies showing more favorable results (possibly due to differences in subject populations). However, taken as a whole, this review as well as a recent Cochrane review [97] , suggests modest efficacy with abstinent alcoholics (i.e., those who were able to abstain for at least a few days prior to initiating medication). Fifth, a majority of studies support the efficacy of oral naltrexone over placebo. Injectable naltrexone shows efficacy but the number of studies are limited. Sixth, while some studies suggest that patients do better with extensive psychosocial treatments added to medications, others show that brief support (as would be appropriate in most medical settings) can be equally effective.
In medical settings, current research suggests either oral naltrexone, topiramate (used off-label), or acamprosate (with abstinent patients) as the initial pharmacotherapy consideration in patients without contraindications to their use. Disulfiram can be considered with motivated, abstinent patients if daily supervision of ingestion is feasible. Brief compliance-oriented support should accompany medication treatment, although some patients may require more extensive adjunctive psychosocial treatment. Systematic evidence on specific populations that may or may not require more extensive psychosocial interventions is lacking. There is evidence to suggest, however, that, in the absence of the availability of intensive psychological help, medication plus brief support from a medical provider can lead to clinical improvement.
While these conclusions are based on a comprehensive search of the literature, it should be noted that non-English language articles and unpublished papers were excluded. Also, article screening, data abstraction, and Jadad ratings were not blinded, which may introduce a potential bias. However, there is evidence that blinding does not alter reviews of this nature [98] .
The challenge in producing conclusions from a review of this nature is the heterogeneity of the patient populations under study. Variations in severity of dependence, genetic polymorphisms, gender, psychiatric comorbidities, and history of alcohol dependence may influence treatment response. Indeed, recent evidence indicates that genetic factors may predict treatment response to naltrexone [99] .
Another major difficulty in comparing studies is the lack of uniformity of drinking outcome measures. In addition, definitions for outcomes such as "heavy drinking days" or "relapse" vary from study to study. The need for consensus on the most clinically relevant drinking outcome measures and a standardized format for reporting these data is essential. In addition, a potential limitation of published clinical trials on treatment of alcohol dependence is the limited length of follow-up (refer to Tables 2 through 7). Follow-up of all these studies is problematic since many are of only a 3-to 6-month duration. In particular, longer-term effects on morbidity and mortality should be investigated in future studies but, as yet, have not been quantified.
Most studies include some type of psychosocial treatment along with medications, but often such treatments are not described in detail, with little information on frequency and duration of treatment. Too few studies are available that examine the separate effects of these treatments on medication efficacy.
Overall, pharmacotherapy for alcohol dependence in primary and specialty care settings appears to be feasible and has the potential to improve patient outcomes. Unfortunately, while alcohol medications with brief interventions have demonstrated efficacy, few trials have been conducted in primary care. Issues that require further study include the identification of patients who are most likely to respond to certain medications, whether medication alone (i.e., without even brief psychosocial interventions) can be effective, compliance problems, and adoption and implementation issues in busy medical practice settings.
